A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients (Neutra4)
Sponsor: Vera Therapeutics, Inc.
Listed as NCT04294472, this PHASE2 trial focuses on BK Virus Infection and remains completed. Sponsored by Vera Therapeutics, Inc., it has been updated 15 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Completed PHASE2
▶ Show 10 earlier versions
-
Sep 2022 — Jun 2023 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
May 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Feb 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE2
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Vera Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .